Significant reduction in hives in CUPID-A and CUPID-C at Week 24
CUPID-A (12+ YEARS)
HSS7 - WEEKLY HIVES
(Week 24, secondary endpoint)1,2
Mean HSS7 at baseline—DUPIXENT: 15.85 (SD, 3.76); placebo: 15.03 (SD, 4.81).2
- Nominal difference observed at Week 12 (DUPIXENT: -8.60 vs placebo: -5.65)
In CUPID-A, definitive conclusions cannot be made for Week 12 as the analysis occurred after the breakdown in the hierarchical testing procedure.
CUPID-C (12+ YEARS)
vs 31% reductiona in HSS7 at Week 24
(DUPIXENT: -7.16 vs placebo: -5.15; P=0.0450, secondary endpoint)1,2
- Reductiona in HSS7 at Week 12 (DUPIXENT: -5.62 vs placebo: -4.31, secondary endpoint; not significant)2
- Mean HSS7 at baseline: DUPIXENT (n=73): 13.31 (SD, 4.43); placebo (n=75): 12.90 (SD, 4.98)2
Definitive conclusions cannot be made for Week 12 as the analysis was not multiplicity controlled.
aLSM change from baseline.
Use of DUPIXENT for the CSU indication in patients aged 2-11 years is supported by evidence from two studies of DUPIXENT in CSU patients 12+ years of age.1
See efficacy across key measures
Hives severity score (HSS) is a patient-reported assessment rated on a scale of 0 (none), 1 (<20 hives), 2 (20 to 50 hives), and 3 (>50 hives). HSS7 is the sum of the preceding 7 days’ hives scores, for a total HSS7 range of 0 to 21.2
See which patients with CSU may be appropriate for DUPIXENT
CSU, chronic spontaneous urticaria; HSS7, hives severity score over 7 days; LSM, least squares mean; SD, standard deviation; UAS7, urticaria activity score over 7 days.